A Phase III, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide CC-92480, Bortezomib And Dexamethasone MEZIVd Versus Pomalidomide, Bortezomib And Dexamethasone PVd In Subjects With Relapsed Or Refractory Multiple Myeloma RRMM: SUCCESSOR-1

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05519085

Study #:
STUDY00149936

Start Date:
Sep 05, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05519085

View Complete Trial Details & Eligibility at ClinicalTrials.gov